Abstract
Background. Germinated barley foodstuff (GBF) is a prebiotic foodstuff that effectively increases luminal butyrate production by stimulating the growth of protective bacteria. In the first pilot study, GBF has been shown to reduce both clinical activity and mucosal inflammation in ulcerative colitis (UC). The aim of this study was to investigate the efficacy of GBF in the treatment of UC in a multicenter open control trial. Methods. Eighteen patients with mildly to moderately active UC were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20–30 g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal micro-flora were also analyzed. Results. After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum. Conclusions. Oral GBF therapy may have the potency to reduce clinical activity of UC. We believe that these results support the use of GBF administration as a new adjunct therapy for UC.
Similar content being viewed by others
References
Hanauer SB. Medical therapy for ulcerative colitis. Curr Opin Gastroenterol 2000;16:324–8.
Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clin North Am 1995;24:475–507.
Gionchett P, Rizzello F, Campieri M. Probiotics in gastroenterology. Curr Opin Gastroenterol 2002;18:235–9.
Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103–8.
Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635–9.
Dickinson RJ, O’Connor HJ, Pinder I, Hamilton I, Johnson D, Axon ATR. Double-blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380–4.
Sartor RB. Microbial factors in the pathogenesis of Crohn’s disease, ulcerative colitis, and experimental intestinal inflammation. In: Kirsner JB, Shorter RG, editors. Inflammatory bowel disease. 4th ed. Baltimore: Williams and Wilkins; 1995. p. 96–124.
Videla S, Vilaseca J, Guarner F, Salas A, Treserra F, Crespo E, et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994;35:1090–7.
Fukuda M, Kanauchi O, Araki Y, Mitsuyama K, Takagi K, Toyonaga A, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med 2002;9:65–70.
Fernandez BF, Hinojosa J, Sanchez LJL, Navarro E, Martinez SJF, Garcias PA, et al. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the study of Crohn’s disease and ulcerative colitis (GETECCU). Am J Gastroenterol 1999;94:427–33.
Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. Scand J Gastroenterol 1991;26:747–50.
Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 980;2:712–15.
Vernia P, Gnaedinger A, Hauck W, Breuer RI. Organic anions and the diarrhea of inflammatory bowel disease. Dig Dis Sci 1988;33:1353–8.
Scheppach W, Sommer H, Kirchner T, Paganelli G-M, Bartram P, Christi S, et al. Effect of butryrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51–6.
Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas A, et al. Short-chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo-controlled trial. Gut 1997;40:485–91.
Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000;15:489–93.
Mitsuyama K, Saiki T, Kanauchi O, Iwanaga T, Tomiyasu N, Nishiyama T, et al. Treatment of ulcerative colitis with germinated barley foodstuff: a pilot study. Aliment Pharmacol Ther 1998;12:1225–30.
Kanauchi O, Iwanaga T, Mitsuyama K. Germinated barley foodstuff feeding; a novel neutraceutical therapeutic strategy for ulcerative colitis. Digestion 2000;63:60–7.
Araki Y, Andoh A, Fujiyama Y, Kanauchi O, Bamba T. Effects of germinated barley foodstuff on microflora and short-chain fatty acid production in dextran sulfate sodium-induced colitis in rats. Biosci Biotechnol Biochem 2000;64:1794–800.
Kanauchi O, Agata K, Fushiki T. Mechanism for the increased defecation and jejunum mucosal protein content in rats by feeding germinated barley foodstuff. Biosci Biotech Biochem 1997;61:443–8.
Kanauchi O, Iwanaga T, Andoh A, Araki Y, Nakamura T, Mitsuyama K, et al. Dietary fiber fraction of germinated barley foodstuff attenuated mucosal damage and diarrhea, and accelerated the repair of the colonic mucosa in an experimental colitis. J Gastroenterol Hepatol 2001;16:160–8.
Kanauchi O, Agata K. Protein and dietary fiber-rich new foodstuff from brewer’s spent grain increased excretion of feces and jejunum mucosal protein content in rats. Biosci Biotech Biochem 1997;61:29–33.
Bamba T, Kanauchi O, Andoh A, Mitsuyama K, Fujiyama Y. New prebiotic from germinated barley for nutraceutical treatment in ulcerative colitis. J Gastroenterol Hepatol 2002;17:818–24.
Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955;2:1041–8.
Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer H, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1839–45.
Harig JM, Soergel KH, Komorowski RA, Wood GM. Treatment of diversion colitis with short-chain fatty acid irrigation. N Engl J Med 1989;320:23–8.
Kanauchi O, Fujiyama Y, Mitsuyama K, Araki Y, Ishii T, Nakamura T, et al. Increased growth of Bifidobacterium and Eubacterium by germinated barley foodstuff, accompanied by enhanced butyrate production in healthy volunteers. Int J Mol Med 1999;3:175–9.
Kanauchi O, Andoh A, Iwanaga T, Fujiyama Y, Mitsuyama K, Toyonaga A, et al. Germinated barley foodstuffs attenuate co-Ionic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model in HLA-B27 transgenic rats. J Gastroenterol Hepatol 1999;14:1173–9.
Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J Gastroenterol Hepatol 2000;15:61–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kanauchi, O., Suga, T., Tochihara, M. et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J Gastroenterol 37 (Suppl 14), 67–72 (2002). https://doi.org/10.1007/BF03326417
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03326417